$ Value
$0
Shares
21,923
Price
$0
Filed
Jul 17
Insider
Name
Issa Mohamed Khairie
Title
EVP, Head of US Oncology
CIK
0002050035
Roles
Transaction Details
Transaction Date
2025-07-15
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
21,923
Footnotes
Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. | Including the July 15, 2025 grant, this includes an aggregate of 85,252 shares of common stock issuable pursuant to previously reported RSUs that have not vested. | Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. | The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Filing Info
Issa Mohamed Khairie's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-07-15 | INCY | A | $0 |
| 2025-07-15 | INCY | A | $0 |
| 2025-07-15 | INCY | A | $0 |
| 2025-06-30 | INCY | A | $0 |
Other Insiders at INCY (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| HARRIGAN EDMUND | — | — | 2026-03-31 |
|
CAGNONI PABLO J
President, Global Head of R&D
|
— | $1.8M | 2026-04-17 |
| BAKER BROS. ADVISORS LP | — | — | 2026-03-31 |
| Clancy Paul J | — | — | 2026-03-31 |
|
Meury William
Chief Executive Officer
|
— | — | 2026-04-15 |
|
Stein Steven H
CMO & Head of Late-Stage Dev.
|
— | — | 2026-04-15 |
|
Trotta Matteo
EVP, GM, Dermatology US
|
— | — | 2026-03-25 |